In this study, we suggest a possibility of the mechanism for stabilizing PLK1 expression by the METTL3–IGF2BP2 pathway in pancreatic adenocarcinoma, which may be a new therapeutic target. This evidence concerns the gene METTL3 and pancreatic adenocarcinoma.